Literature DB >> 18282149

The paradoxical association between inherited factor VII deficiency and venous thrombosis.

S Marty1, C Barro, B Chatelain, B Fimbel, B Tribout, J Reynaud, J-F Schved, M Giansily-Blaizot.   

Abstract

Inherited factor VII (FVII) deficiency is considered to be a haemorrhagic disease. Nonetheless, some patients paradoxically present with venous thrombosis. We assessed whether there was a link between phenotype and genotype in seven patients with inherited FVII deficiency and thrombosis (eleven venous thrombotic events). For each patient (FVII:C < 50%), clinical data were collected, aetiological assessment of risk factors for thrombosis was investigated, and direct sequencing of the nine exons and promoter of the FVII gene (F7) was performed. We present the second series ever published on FVII patients with thrombosis. In nine of the eleven thrombotic events, there was at least one classical triggering risk factor; clinical (n = 4), familial antecedent (n = 2), or biological, defined by phospholipid-binding antibodies or elevated FVIII:C levels (n = 7). In contrast to a previous series, only two events occurred after surgery, performed both with and without replacement therapy. The thrombotic event remained unexplained in one young patient, highlighting the lack of 'protection' against venous thrombosis by low FVII:C levels. Genetic mutations were found to be heterogeneous. Among the seven F7 sequence alterations identified in the present study, only two (p.Ala354Val and p.Arg364Gln) have previously been reported in FVII-deficient patients presenting with venous thrombosis. Our genetic analyses of the F7 mutations in these patients show the complexity of FVII deficiency associated with thrombosis. These data justify a holistic, clinical and biological approach for patients with these specific symptoms. This series also strongly suggest that mild FVII deficiency should not prevent physicians from using antithrombotic prophylaxis in FVII-deficient patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18282149     DOI: 10.1111/j.1365-2516.2007.01647.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  12 in total

Review 1.  Paradoxical thrombosis part 1: factor replacement therapy, inherited clotting factor deficiencies and prolonged APTT.

Authors:  Giuseppe Lippi; Emmanuel J Favaloro; Massimo Franchini
Journal:  J Thromb Thrombolysis       Date:  2012-10       Impact factor: 2.300

2.  The association between thrombophilic gene mutations and recurrent pregnancy loss.

Authors:  Ahmad Poursadegh Zonouzi; Nader Chaparzadeh; Saeid Ghorbian; Mahzad Mehrzad Sadaghiani; Laya Farzadi; Alieh Ghasemzadeh; Taiebeh Kafshdooz; Masoud Sakhinia; Ebrahim Sakhinia
Journal:  J Assist Reprod Genet       Date:  2013-08-29       Impact factor: 3.412

3.  [Hereditary heterozygous factor VII deficiency in patients undergoing surgery : Clinical relevance].

Authors:  D Woehrle; M Martinez; D Bolliger
Journal:  Anaesthesist       Date:  2016-09-01       Impact factor: 1.041

4.  Haplotype and genotype effects of the F7 gene on circulating factor VII, coagulation activation markers and incident coronary heart disease in UK men.

Authors:  G Ken-Dror; F Drenos; S E Humphries; P J Talmud; A D Hingorani; M Kivimäki; M Kumari; K A Bauer; J H Morrissey; H A Ireland
Journal:  J Thromb Haemost       Date:  2010-11       Impact factor: 5.824

Review 5.  Congenital FVII deficiency and thrombotic events after replacement therapy.

Authors:  Antonio Girolami; Irene Bertozzi; Ignazio Rigoni; Rodolfo Muzzolon; Silvia Vettore
Journal:  J Thromb Thrombolysis       Date:  2011-10       Impact factor: 2.300

Review 6.  Associated prothrombotic conditions are probably responsible for the occurrence of thrombosis in almost all patients with congenital FVII deficiency. Critical review of the literature.

Authors:  A Girolami; F Tezza; R Scandellari; S Vettore; B Girolami
Journal:  J Thromb Thrombolysis       Date:  2010-08       Impact factor: 2.300

Review 7.  The clinical significance of the lack of arterial or venous thrombosis in patients with congenital prothrombin or FX deficiency.

Authors:  Antonio Girolami; Nicole Candeo; Silvia Vettore; Anna Maria Lombardi; Bruno Girolami
Journal:  J Thromb Thrombolysis       Date:  2010-04       Impact factor: 2.300

Review 8.  Rare congenital bleeding disorders.

Authors:  Massimo Franchini; Giuseppe Marano; Simonetta Pupella; Stefania Vaglio; Francesca Masiello; Eva Veropalumbo; Vanessa Piccinini; Ilaria Pati; Liviana Catalano; Giancarlo Maria Liumbruno
Journal:  Ann Transl Med       Date:  2018-09

9.  Evaluation of the Antihemostatic and Antithrombotic Effects of Lowering Coagulation Factor VII Levels in a Non-human Primate.

Authors:  Michael Wallisch; Sven R Olson; Jeffrey Crosby; Jennifer Johnson; Susan F Murray; Joseph J Shatzel; Erik I Tucker; Owen J T McCarty; Monica T Hinds; Brett P Monia; András Gruber
Journal:  Cell Mol Bioeng       Date:  2020-03-23       Impact factor: 2.321

10.  Anticoagulation Therapy Considerations in Factor VII Deficiency.

Authors:  Eric Paulus; Kathy Komperda; Gabriel Park; Julie Fusco
Journal:  Drug Saf Case Rep       Date:  2016-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.